GSK-626616

GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM) . GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia[1].

Product Specifications

CAS Number

[1025821-33-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DYRK

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/gsk-626616.html

Purity

99.77

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N=C(NC2=C(Cl)C=CC=C2Cl)S/C1=C\C3=CC=C4N=CC=NC4=C3

Molecular Formula

C18H10Cl2N4OS

Molecular Weight

401.27

Precautions

H302, H315, H319, H335

References & Citations

[1]Connie L. Erickson-Miller, et al. GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia. Blood 2007 110:510; |[2]Wippich F, et al. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell. 2013;152 (4) :791-805.